All articles tagged with #litfulo
Pfizer's Litfulo has been approved by the FDA for the treatment of alopecia areata in people aged 12 and above. The drug is also being tested for vitiligo, ulcerative colitis, and Crohn's disease. Regulatory decisions are expected in the EU, UK, Canada, and Japan later this year.
The FDA has approved LITFULO, a hair loss drug, to treat alopecia areata, an autoimmune disease that causes hair loss on the scalp, face, and body. The drug is approved for adults and adolescents aged 12 and over with severe alopecia areata. The drug inhibits two types of enzymes, blocking inflammatory signaling and cell-killing activity from T cells, which have been implicated in the development of alopecia areata. The clinical trial showed a statistically significant increase in hair coverage for those taking 50 mg of LITFULO compared to placebo.
The FDA has approved the first and only medication for severe alopecia areata, or at least 50% hair loss, for Americans under 18. The once-daily pill called Litfulo, created by Pfizer, has shown to be effective in regaining hair coverage on the scalp. The approval will help substantiate alopecia areata as more than just something that’s cosmetic, which has been considered that for years by insurers who may not want to cover the therapies. A full year's supply has a list price of $49,000, according to Pfizer.